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ABSTRACT OF THE DISSERTATION
Small Molecule Inhibitors of HPV16 E6
by
Chung-Hsiang Yuan
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2013
Penelope Duerksen-Hughes, Chairperson

High-risk human papillomaviruses (HR-HPVs) cause nearly all cases of cervical
cancer. HPV 16 E6, one of two viral oncogenes, protects cells from apoptosis by binding
to and accelerating the degradation of several apoptotic proteins, including caspase 8 and
p53. We proposed that blocking the interactions between HPV E6 and its partners using
small molecules had the potential to re-sensitize HPV+ cells to apoptosis. To test this
prediction, we screened libraries of small molecules for candidates that could block
E6/caspase 8 binding, and identified several candidates from different chemical classes.
Testing hits for dose-dependency and specificity in vitro and for toxicity in a cell-based
assay allowed us to select the two best candidates, myricetin and 6,7-dihydro-1Himidazo[4,5-c] pyridine-6-carboxylic acid (DIPC), for further testing. Both compounds
significantly and specifically inhibited the ability of E6 to bind in vitro to both caspase 8
and to E6AP, the protein that mediates p53 degradation. In addition, both compounds
were able to increase caspase 3/7 activity and to sensitize HPV+ SiHa cells, but not HPVC33A cells, to apoptosis induced by TRAIL, a cancer-specific ligand, as well as the
chemotherapeutic agents doxorubicin and cisplatin. New therapies based on this work
may improve treatment for HPV+ cancer patients.
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CHAPTER ONE
INTRODUCTION

Human Papillomavirus Infections and Cancer
Human papillomaviruses (HPV) are small, double stranded DNA viruses that
infect epithelial tissues, including those of the anogenital tract. Of the more than 200
different identified types of HPV, about 40 are involved in genital tract infections. Some
types of HPV cause warts, while others can increase the risk of malignancy and lead to
cancer of the cervix, other anogenital regions, and the head and neck areas [1]. HPV
types are classified as either high risk or low risk, with high-risk types being associated
with cancer formation while low risk types are not. For example, HPV types 6 and 11 are
classified as low risk types, and infection with these types results in the proliferation of
epithelial cells and manifests as warts or papillomas on the skin. However, these
infections are generally self-limiting and do not lead to malignancy. On the other hand,
HPV types 16 and 18 are major high-risk genotypes, which together cause up to 75% of
cervical cancer cases as well as a significant number of head and neck squamous cell
carcinomas. The association between HPV and human cancer has been studied for more
than three decades. HPV-induced cervical cancer is the second most common cancer and
the fifth leading cause of cancer-related deaths among women worldwide [2, 3]. Cervical
cancer is not the only cancer caused by high-risk types of HPV; in fact, biological and
functional studies have demonstrated the role of HPV in the development of several
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additional types of cancer, such as cancer of the head and neck, vaginal, vulvar, anal, and
penile areas [4, 5].
When high-risk HPV infects young females, most infections cause no or only
minor symptoms, and usually disappear without any treatment within a few years.
However, in 5% to 10% of infected women, the infection can persist for many years [6].
Persistent infections are at relatively high risk for causing cell abnormalities and
developing lesions of the cervix, which can in turn lead to the development of cervical
cancer. In 2010, 12,000 women in the United States were diagnosed with HPV-induced
cervical cancer, of which 4000 were expected to die. Furthermore, cervical cancer is the
second most common cancer in women worldwide. There are approximately 400,000
new cases of this disease diagnosed each year and approximately half of these patients
will die. The development of HPV-induced cervical cancer usually requires 15–20 years,
providing a window of opportunity for detecting the presence of HPV and/or HPVinduced cell abnormalities.
Unfortunately, current approaches for the prevention and treatment of HPVassociated malignancies are not always effective. Significant progress has been made
with regards to prevention, in that two vaccines that target high-risk HPVs, Cervarix and
Gardasil, have both demonstrated remarkable efficacy in preventing infection within the
vaccinated population [7]. These vaccines have been shown to reduce the infection rate
(by at least 90%), as well as the incidence of early neoplasia, caused by the targeted HPV
types (HPV type 16 and 18 in the case of Cervarix; HPV types 6, 11, 16, and 18 in the
case of Gardasil) [8-10]. However, because these vaccines are prophylactic rather than
therapeutic, they are not effective interventions for patients already infected with HPV.
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Surgical and ablative techniques are available for these patients, including excision,
electro- and cryosurgery, and laser-based treatments. However, these procedures are
invasive and cytodestructive, and lesions frequently recur following treatment. Combined
chemoradiotherapies have also been assessed, but with mixed results. Topical treatments
for warts are available, and include trichloroacetic acid, liquid nitrogen, imiquimod,
interferon- injections and podophyllin resin [11]. However, repeated treatments are
again necessary, treatment is not always effective, and imiquimod is not approved for use
in the oral cavity. Also, while these treatments may remove warts, they do not cure the
HPV infection itself. Viral DNA can be detected before cell abnormalities are observed,
and the Papanicolaou test, also called a Pap smear or Pap test, is used to screen and detect
abnormal cells, possible precursors for malignancies. However, Pap tests may not always
detect the abnormal cells. First, the sample may not contain abnormal cells that may be
present on the cervix. Second, the abnormal cells may exist high up in the cervix or deep
in the glands of the cervix (adenocarcinoma), and it is difficult to obtain samples from
these areas. Due to the limitations of current approaches, therefore, there remains an
urgent need for the development of effective and novel therapies that are based on a solid
understanding of the biology of the virus.

HPV Virology
HPV Genes and Proteins
The HPV genome is divided into an early region (E), a late region (L) and a noncoding long control region (LCR) (Figure 1A). The E region encodes seven nonstructural proteins: E1, E2, E4, E5, E6, E6* and E7, while the L region encodes two
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structural proteins: L1 and L2, which code for the major and minor capsid proteins,
respectively. Early genes are responsible for modulating epithelial cell function so as to
favor virus production. For example, their gene products modulate keratinocyte
differentiation, promote viral DNA replication and segregation, and inhibit viral
clearance by the immune system. All early HPV proteins perform multiple functions, and
act by interacting with a variety of cellular partners [12, 13]. These interactions in turn
modify the flow through numerous cellular pathways, including apoptosis. The core
proteins of the late genes, L1 and L2, together with HPV DNA, participate in the
assembly of virus particles.

HPV Life Cycle
HPV infects cells in the basal layer, below the surface of the epithelium, and
carries out a life cycle that is closely tied to the differentiation program of the host cell
(Figure 1B). During the early stages of infection, the episomal viral genome is usually
present at fewer than 100 copies per cell, and functions as a slowly replicating plasmid.
Shortly after infection and uncoating, low-level expression of early genes (E6, E6*, E7,
E1 and E2) as directed by the early promoter enables maintenance of the episomal state
of the HPV genome [14-18].
As cells move up through the layers, they begin to proliferate. The ability of E6
and E7 to suppress apoptosis and to alter the function of factors involved in cell-cycle
regulation, respectively, facilitates prolongation of the proliferative stage of keratinocyte
differentiation [19, 20]. During this proliferative stage, E1 and E2 function to regulate
viral DNA replication and transcription such that viral DNA is replicated coordinately
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with the host cell chromosome. E2 binds to the HPV upstream regulatory region and
recruits the E1 DNA helicase to the viral origin of replication. In addition, E2 acts to bind
the necessary factors onto mitotic chromatin and to tether the virus genome to host
chromosomes during mitosis [21]. Meanwhile, E1 binds to the viral origin of replication.
It then uses ATP to unwind double-stranded DNA, acting like a helicase.
Amplification of viral genomes begins in the proliferative layers, and an
increased level of expression of all the early viral gene products, including E4 and E5
[22-24], is necessary for this process. During this stage, an increase in transcription of the
genes coding for the E1, E2, and E1-E4 fusion proteins is observed [25, 26]. The
sequence of E4 is located entirely within the E2 open reading frame (ORF), and the
protein is expressed relatively late during viral infection. E2 is co-expressed with and
binds to E1^E4 protein and this interaction results in the stabilization of both proteins
[27]. Overexpression of the E1^E4 protein enables reorganization of keratin network
during keratinocyte differentiation and viral genome amplification [28].
Both the E4 and E5 proteins participate in the late viral functions, although details
of these mechanisms are not yet entirely defined. It has been shown that E5 plays a subtle
role during the productive stage of the HPV16 life cycle [23, 29]. When the infected cells
reach the point of terminal differentiation, the viral copy number is increased up to a
thousand per cell, and the late genes L1 and L2, which encode viral capsid proteins, are
expressed. The viral capsid proteins assemble into virus particles and are released and
spread to other host cells. Through these mechanisms, HPV is able to enhance the
survival of infected cells in order to facilitate its own replication cycle, and thus ensure
the production and spread of progeny.
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Figure 1 (A) Genomic map of HPV 16 (B) Viral gene expression following HPV
infection. Taken from Doorbar et al, 2006 [30].
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Integration and Cancer
During the normal viral life cycle, the HPV genome exists in host cells as an
episome. In rare cases, however, integration of the viral genome into that of the host can
occur. Interestingly, this integration is not required for the HPV life cycle and is, in fact,
detrimental to the virus, as integrated viral sequences do not reproduce. However,
integration is closely tied to the development of cancer, as most cases of HPV-induced
cervical cancer feature an integrated form of the HPV genome. Such integration typically
leads to an increase in the expression of HPV early proteins, including the E6 and E7
oncoproteins, and a consequential increase in cellular transformation and the probability
of HPV induced carcinogenesis [31]. The activities of E6 are of particular relevance to
cancer development, because E6 functions to block both intrinsic and extrinsic apoptosis.

Apoptosis
Apoptosis, also known as programmed cell death, plays an important role in
development, cellular homeostasis and the pathophysiology of many diseases [32].
Apoptosis helps to eliminate damaged cells and also contributes to the elimination of
virus-infected cells [33]. If inappropriately up- or down-regulated, apoptosis can also
contribute to various diseases such as autoimmunity and cancer [34]. Two major classic
apoptotic pathways have been identified: the extrinsic pathway, triggered by the
engagement of “death receptors”, and the intrinsic pathway, which responds to a variety
of stress signals (for example, radiation) by triggering the release of intracellular signals
that promote cell death [35-37].
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Extrinsic Pathway
Apoptosis is triggered through the extrinsic pathway when specific receptors are
activated by their corresponding ligands. The majority of these “death” ligands belong to
the TNF (tumor necrosis factor) family, and their corresponding cell surface “death”
receptors to the TNF receptor family. TNF-alpha binds to TNF R1 or R2 receptors, Fas
ligand to Fas, and TRAIL (TNF-related apoptosis-inducing ligand) binds to Death
Receptor (DR) 1, DR2, DR3, DR4, and DR5. Other receptors within this family include
FADD-like interleukin-1 beta-converting enzyme (FLICE) and TNF-like weak inducer of
apoptosis (TWEAK) [38]. Adaptor molecules such as TRADD (Tumor necrosis factor
receptor type 1-associated DEATH domain protein) and FADD (Fas-Associated protein
with Death Domain) are engaged, and initiator caspases such as procaspase-8 are
activated. Interactions of regions such as the death domain (DD) allow TRADD, FADD,
and pro-caspase 8 to combine to form the death-inducing signaling complex (DISC) [39].
Formation of the DISC enables cleavage of caspase-8, which then cleaves and activates
executioner caspases such as procaspase-3/7. The active caspase-3/7 can cleave many
different target substrates, including poly(ADP-ribose) polymerase (PARP), and these
cleavages lead to the demise of the cell. PARP is a nuclear enzyme that catalyzes the
transfer of the ADP-ribose moiety of NAD+ to a specific subset of nuclear substrates in
response to DNA damage. Active caspase-3 cleaves PARP into 24 kDa and 89 kDa
segments, thereby eliminating the ability of PARP to function in DNA repair and thus
promoting apoptosis. In the case of Fas-mediated apoptosis, two pathways have been
shown to operate in a cell type-dependent manner (types I and II) [40]. In the type I cell
model, a robust activation of caspase-8 can be observed following DISC formation.
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Overexpression of anti-apoptotic proteins such as Bcl-2 or Bcl-XL cannot stop the
cleavage of caspase-8 and caspase-3, and mitochondrial activity is not required to trigger
apoptosis in type I cells. In contrast, DISC formation in type II cells is weak, and
additional signaling from the mitochondria is necessary for apoptosis. Low levels of
DISC and capsase-8 are detected in type II cells. In this context, caspase-8 cleaves Bid
and triggers mitochondrial depolarization and the release of cytochrome c. Following its
release, cytochrome c forms a complex with apoptosis protease activating factor 1, (Apaf1) and procaspase-9, called the apoptosome. The apoptosome is analogous in function to
the DISC, and mediates the activation of caspase-9, which in turn activates caspase-3.
The intracellular events of apoptosis then give way to the external characteristics of this
form of cell death, which include chromatin condensation, phosphatidlyserine exposure,
cytoplasmic shrinkage and membrane blebbing. Anti-apoptotic proteins such as Bcl-2
and Bcl-XL can block the activation of caspase in type II cells and significantly reduce
apoptosis [40, 41]. For ligands other than those of the TNF family, initiator caspases
include capsase-10 and caspase-2, and the corresponding adaptor proteins are RIP,
RAIDD/CRADD, and TRAFS. In most of these cases, activation of the executor caspases
3/7 initiates the apoptotic cascade [42-45].

Intrinsic Pathway
The classic intrinsic apoptotic pathway, also referred to as the mitochondrial
pathway, can respond to a variety of external stimuli such as DNA damage, radiation and
osmotic stress [46, 47]. Activation of this pathway results in the release of cytochrome c
from the mitochondrial intermembrane space to the cytosol. Apoptotic protease activating
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factor-1 (Apaf-1), pro-caspase 9 and cytochrome c then form a complex called the
apoptosome in the cytosol [48, 49]. The binding of Apaf-1 and cytochrome c to
procaspase-9 leads to the auto-cleavage and activation of procaspase-9. The active
caspase-9 then cleaves and activates caspase-3, which induces the cleavage of additional
substrates, such as PARP gelsolin, and protein kinase C-delta [50-52] (see Figure 2).
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Figure 2. Generalized overview of the extrinsic and intrinsic apoptosis pathways.
The extrinsic pathway is initiated by the binding of a tumor necrosis factor (TNF) family
ligand to its receptor, followed by activation of downstream signaling proteins. In the
intrinsic pathway, cellular stress causes BH3 activation and cytochrome c release. Both
pathways activate the effector caspase-3 and promote cell death. Proteins are identified
within the text [53].
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Virus-Mediated Modulation of Apoptosis
Following infection of host cells, a virus typically employs a number of different
mechanisms to avoid the host immune response and to initiate and maintain efficient
production and spread of its progeny. In most cases, a host organism will attempt to
initiate apoptosis in order to eliminate infected cells. For this reason, many viruses,
especially the DNA viruses, encode a variety of viral proteins that can inhibit or delay
these protective actions, often by targeting key cellular proteins [37]. For example,
human adenovirus employs the E3 14.7 kDa protein to reduce TNF- and Fas-induced
apoptosis; these proteins work by inhibiting the TNFR-induced release of arachidonic
acid [54]. Poxvirus produces two proteins, CrmB and CrmC, that change the
conformation of TNFR in order to block the binding of TNF [55]. In addition, poxvirus
and herpesvirus both encode proteins with homology to the DED domain, and thus block
the binding of death receptors and the FADD adaptor protein to caspase-8 [56]. CD40
and CD40L form a receptor/ligand pair found on antigen presenting and T cells,
respectively, and is required for their activation. Epstein-Barr virus (EBV), a causal agent
of epithelial and lymph tumors, can increase the expression of CD40L but downregulates the expression of CD40. This abnormal interaction between CD40L and CD40
contributes to decreased apoptosis of infected cells and the development of myeloma
cells [57]. Furthermore, the Epstein-Barr nuclear antigen 3C (EBNA3C) is known to
possess anti-apoptotic properties and to regulate cell proliferation. For example,
EBNA3C can bind to p53 and Gemin3 so as to inhibit the binding between p53 and
DNA, thus blocking the p53-mediated apoptotic pathway [58]. HPV also expresses
several proteins that affect cellular apoptotic pathways, as detailed below.
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HPV Proteins That Modulate Apoptosis
Apoptosis is an important mechanism through which the host can eliminate
infected cells, and the ability to avoid apoptosis can therefore enhance virus survival. In
addition, apoptosis plays an important role during keratinocyte differentiation [59]. For
these reasons, it is to the virus’ advantage to intervene in apoptotic pathways, and five
papillomavirus proteins, E2, E5, E6, E6* and E7, have been shown to do so. E5 and E6
can protect host cells from apoptosis, while E2 and E6* appear to possess pro-apoptotic
properties. E7 can act in either a pro-apoptotic or an anti-apoptotic manner, depending on
the cell type and circumstances. While it is not entirely clear why pro-apoptotic
properties of virus proteins might enhance virus survival and propagation, it is likely that
the influence of each HPV protein on host apoptotic pathways is related to specific stages
of the virus life cycle. Overexpression of the major oncogenes, E6 and E7, during cell
transformation generally results in resistance of transformed cells to apoptosis; this
ability to avoid apoptosis is one of the major hallmarks of carcinogenesis [60].

HPV E6
The essential oncoprotein HPV E6 has been widely studied over the last two to
three decades. E6 is a small protein, consisting of 151 amino acids and presenting two
atypical zinc fingers with motifs that contain two cysteines (Cys-X-X-Cys). The p53
tumor suppressor is the first-described and best-known target of HPV E6 [61]. p53 acts as
a transcriptional factor, and can trigger cell cycle arrest or apoptosis in response to
cellular stress or DNA damage. Under normal conditions, triggers such as DNA damage
cause increases in the level of p53, which then lead to downstream effects such as cell
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cycle arrest and/or apoptosis, depending on the intensity or amplitude of the damage or
stimulus. The presence of E6 from high-risk types of HPV interferes with this process,
because E6 binds to both p53 and the E6-associated protein ligase (E6AP), causing
ubiquitinylation and the subsequent degradation of p53. This loss then prevents p53 from
inducing either growth arrest or apoptosis of infected cells [62]. During this process, E6
first binds to E6AP, which functions as an E3 ubiquitin protein ligase. Then, the
E6/E6AP complex binds to the core domain of p53. E6AP catalyzes the transfer of
ubiquitin to p53, thereby enabling its proteasome-mediated degradation. This E6mediated inhibition of p53 activity can increase the survival of transformed cells [63, 64].
Interestingly, a recent study showed that E6 could also interact with ubiquitin ligases
other than E6AP in order to promote p53 degradation [65].
In addition to p53, E6 also interacts with other partner proteins that play a variety
of roles in the cell [12, 66]. Following binding to E6, many of these proteins are lost by
an E6AP-mediated ubiquitinylation and degradation process similar to that observed for
p53. E6 partners include proteins involved in apoptosis such as Bak [67], c-Myc [68],
TNF receptor 1 (TNF-R1) [69], FADD, and caspase-8 [12, 70-72]. Bak and Myc were the
first apoptosis-related proteins, other than p53, to be identified as targets of E6.
Following binding to E6, both Bak and Myc are degraded through the ubiquitinproteasome pathway [68]. This loss of Bak has biological consequences, as E6 has been
shown to inhibit TNF-mediated apoptosis by reducing the expression of Bak in a process
independent of the regulation of caspase-3 and caspase-8 expression [73]. Other key
proteins involved in cellular apoptosis can also be compromised by E6. For example, E6
can bind to the death effector domains (DEDs) of FADD and procaspase-8 and accelerate
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their degradation [70-72, 74]. The resulting lower amounts of FADD and procaspase 8 in
E6-expressing cells then hinders formation of the apoptotic Death Inducing Signaling
Complex (DISC) that would normally be triggered by members of the TNF superfamily,
thereby compromising the ability of TNF, FasL and TRAIL to initiate apoptosis [69, 70,
72, 75]. In addition, E6 exerts effects on other apoptotic and anti-apoptotic proteins at the
transcriptional level. For example, E6 can up-regulate the activity of the survivin
promoter [76].
In each of these cases, E6 functions to reduce cell death by compromising the
integrity of cellular pathways leading to apoptosis. In the context of the virus life cycle,
the prevention of apoptosis is critical because it protects infected cells from elimination
by the immune system, and therefore enables them to continue serving as hosts. This
ability may also prolong the early stages of the life cycle. During carcinogenesis, the
expression of E6 is typically increased, resulting in cells that do not undergo apoptosis
and that are then susceptible to E6 and E7-mediated transformation. One recent study
found that E6-mediated cervical cancer relies on the continuous expression of E7 along
with constitutively expressed E6, and that continuous expression of E7 is required for the
maintenance of cervical cancer and precancerous lesions in transgenic mice [77].
E6 has been considered a promising target molecule for therapy due to its abilities
to block apoptosis and promote cancer development. For this reason, inhibition of E6 is
predicted to lead to more cell death. Some progress was reported in 2004 and 2006
regarding the development of inhibitors of E6-E6AP interactions, a necessary step in the
loss of p53 [78-80]. However, to the best of our knowledge, no group other than our own
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is exploring the possibility of interfering with E6 function by blocking its ability to
inhibit apoptotic signaling.
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HPV E6

Figure 3. Interactions between E6 and apoptotic proteins. E6 binds to apoptotic proteins
that are involved in both extrinsic and intrinsic apoptosis pathways and accelerates their
degradation, thereby blocking apoptotic signal transduction.
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Re-Engagement of Apoptotic Pathways as a Therapeutic
Approach for HPV-Induced Cancers
Currently, therapeutic approaches that rely on activation of either the intrinsic or
the extrinsic apoptotic pathways are unlikely to be helpful for HPV-associated diseases
due to the ability of high-risk E6 proteins to subvert both extrinsic and intrinsic apoptotic
pathways by mediating the rapid degradation of signaling molecules (p53 in the case of
the intrinsic pathway and FADD and caspase 8 in the case of the extrinsic pathway). As a
result of these E6 activities, therefore, engagement of either the extrinsic or the intrinsic
apoptotic pathways does not result in the transduction of the intended death signal
because the mediator molecules are missing. Therefore, if any of these apoptosisinducing signaling pathways are to be used as tools for the elimination of HPV-associated
malignancies, it will be necessary to restore the missing signaling molecules.
An approach based on inhibiting the ability of E6 to mediate the rapid
degradation of its cellular partners has the potential to re-sensitize HPV+ cells to inducers
of apoptosis, and could therefore make certain existing cancer treatments available to
those suffering from HPV-associated malignancies.
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Figure 4. Working model and strategy. (A) TRAIL-mediated apoptotic pathway. The
binding of either TRAIL or antibodies directed against the TRAIL R (e. g., AMG 655) to
DR5 activates the pathway, leading to complex formation, activation of caspase 8 and
initiation of the apoptotic cascade. (B) The HPV E6 proteins binds to p53 (not shown in
figure), FADD and (pro)caspase 8, causing their rapid degradation and thus blocking
apoptotic signaling. (C) Small, drug-like molecules that interfere with the ability of E6 to
interact with caspase 8 and FADD have the potential to rescue the apoptotic pathway and
thus re-sensitize cells to apoptosis.
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Reactivating Intrinsic Apoptosis
Progress has been made in the search for inhibitors of the E6/E6AP interaction;
this approach has the potential to re-activate the intrinsic apoptotic pathway. First, the
essential binding motif through which E6 and E6AP interact was identified and verified
[24, 81, 82]. Structural information regarding the E6/E6AP binding motif was then
transferred to a three-dimensional query format suitable for computational screening of
large chemical databases. This 3D format was used to query the National Cancer Institute
(NCI) open chemical database comprising approximately 240,000 compounds, as well as
the Sigma-Aldrich Library of Rare Chemicals of 97,000 compounds. Selected molecules
that were predicted to fit into the E6/E6AP binding motif were then analyzed for their
ability to inhibit E6/E6AP interactions and thereby interfere with E6-promoted p53
degradation. Following these in vitro and cell-based assays, several compounds with
these characteristics were identified. Although these compounds have the potential for
development into new therapeutic agents for treatment of HPV-associated cancers [79],
no significant progress has been reported for the last several years.

Reactivating Extrinsic Apoptosis
It may also be possible to target the extrinsic apoptotic pathway. For example,
activation of the TRAIL-mediated, extrinsic apoptotic pathway shows promise in the
treatment of several types of tumors. TRAIL-based therapies have elicited significant
interest in recent years, largely due to their apparent ability to kill tumor cells while
sparing most normal cells. Previous studies have reported on the effectiveness of both
TRAIL and -TRAIL R1 and R2 in combination with other sensitizing agents such as
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doxorubicin, bortezomib, adriamcin, 5-fluorouracil, irinotecan hydrochloride, paclitaxel,
carboplatin, gemcitabine, cisplatin and radiation in both cell and animal model systems
[83-86]. Currently, the challenge with using these approaches to target HPV-associated
cancers is similar to the challenge noted above; namely, that E6 targets the mediating
molecules for rapid degradation.
Work from our laboratory over the past decade has demonstrated that E6 can bind
to many components involved in extrinsic apoptosis, including tumor necrosis factor
receptor 1 (TNF R1) [75], the adaptor molecule Fas-associated death domain (FADD)
[70], and procaspase 8 [87]. The binding sites on FADD and caspase 8 were identified
using targeted mutagenesis, and a 23 amino acid peptide corresponding to the E6 binding
site on FADD was designed and synthesized. We then demonstrated that this peptide
could block the interaction between HPV E6 and FADD (and between E6 and caspase 8),
thus re-sensitizing SiHa cells to TRAIL- and Fas-induced apoptosis [74] and providing
proof-of-principle for our proposed approach. However, turning peptides into therapeutic
agents is quite challenging due to well-known issues related to delivery, stability, etc.
Small molecules represent alternative approach, as they have been used
successfully to inhibit important signal transduction pathways involved in breast, colon,
pancreatic and lung cancer formation [88]. Comparing to peptide inhibitors, small
molecules are relatively stable, penetrate more easily into target cells, and are easier to
modify for drug development. Once small molecules block the inhibitory activity of E6,
known triggers of apoptosis, such as TRAIL, could initiate apoptosis of HPV-positive
cells. Such findings suggest that targeting HPV E6 (and/or other HPV oncoproteins)
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could prove an excellent therapeutic strategy to treat HPV-associated cancers, and that
small molecules could prove an appropriate approach to reach this goal.

Purpose of This Study
As previously mentioned, expression of HPV E6 blocks apoptotic signal
transduction by binding to and accelerating the degradation of several apoptotic proteins
including p53, caspase 8, and FADD. This ability of HPV E6 makes cancer therapies that
function by inducing apoptosis ineffective for the treatment of HPV-associated
malignancies. Therefore, in order to discover and develop novel and effective therapeutic
approaches for these malignancies, we sought to identify agents that can block E6
function by addressing the following questions: 1) What kinds of small molecules have
the ability to block the interactions between E6 and its apoptotic protein partners? 2) Can
those small molecules re-sensitize E6-expressing cells to normal apoptotic stimuli?
Results from this study will lay the groundwork for making apoptotic therapies
that function by activating apoptotic pathways, such as TRAIL or other chemotherapy
drugs, available to patients suffering from HPV-associated malignancies. Our
contribution to the field will be the identification of small molecules that, by inhibiting
the binding of E6 to its cellular partners, sensitize tumor cells to apoptosis. This
contribution is significant because it will lay the foundation for developing a novel class
of therapeutic agents effective in HPV-infected individuals. The proposed work will also
lead to insights beyond the field of HPV therapeutics by enhancing our current
understanding of protein/protein interactions and how they can be blocked, HPV virology,
virus/host interactions, and how the cellular pathways affected by HPV normally function.
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Abstract
High-risk strains of human papillomaviruses (HPVs) cause nearly all cases of
cervical cancer as well as a growing number of head and neck cancers. The oncogenicity
of these viruses can be attributed to the activities of their two primary oncoproteins, E6
and E7. The E6 protein has among its functions the ability to prevent apoptosis of
infected cells through its binding to FADD and caspase 8. A small molecule library was
screened for candidates that could inhibit E6 binding to FADD and caspase 8. Flavonols
were found to possess this activity with the rank order of myricetin > morin > quercetin >
kaempferol = galangin >>(apigenin, 7-hydroxyflavonol, rhamnetin, isorhamnetin,
geraldol, datiscetin, fisetin, 6-hydroxyflavonol). Counter screening, where the ability of
these chosen flavonols to inhibit caspase 8 binding to itself was assessed, demonstrated
that myricetin, morin and quercetin inhibited GST-E6 and His-caspase 8 binding in a
specific manner. The structure–activity relationships suggested by these data are unique
and do not match prior reports on flavonols in the literature for a variety of anticancer
assays.
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Introduction
Human papillomavirus (HPVs) are small DNA viruses that infect human
epithelial tissue such as that found in the genital tract, hands, and feet. There are more
than 200 types of HPVs, which can be classified both on the basis of sequence homology,
leading to assignments of species, and on the basis of whether infection with a particular
type is likely to lead to cancer (high-risk vs low-risk). Most, though not all, of the highrisk types are located within species 9 (reviewed in Munoz et al., 2006) [90]. HPV types
16 (species 9) and 18 (species 7) are high-risk types, and are the causative agents of
nearly all cases of human cervical cancer, between 20% and 30% of head and neck
cancer cases, and some cases of other cancers [91-94]. The HPV-encoded oncogenes E6
and E7 are responsible for cellular immortalization and transformation.6–8 While E7 is
best known for the inactivation of the retinoblastoma (Rb) protein and thus for the
immortalization of differentiated cells, E6 induces degradation of p53, which serves as a
critical tumor suppressor. In addition, E6 binds to and inactivates other cellular proteins
involved in normal cellular functions [12, 13, 95, 96].
In our previous work, we found that E6 interacts with the extrinsic apoptosis
pathway by binding to key signaling molecules such as TNF R1, FADD and caspase 8
and altering their functions, thus allowing HPV-infected cells to avoid clearance through
apoptosis [70, 72, 75, 87]. Activation of the extrinsic apoptotic pathway normally begins
with the binding of ligands such as TNF-, FasL or TRAIL to their receptors, which
then leads to recruitment of adaptor proteins such as FADD, TRADD and TRAF. A
Death Inducing Signaling Complex (DISC) is then formed, which includes the initiator
caspase, procaspase-8, bound to the adapter protein FADD. Procaspase 8 cleavage
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releases active cysteine-aspartic proteases, which then enable caspase 8 to cleave and
activate effector caspases such as caspase 3 and 7 and to initiate apoptosis. If the HPVE6
oncoprotein is expressed in the cell, however, this sequence cannot occur. E6 binds to
FADD and procaspase-8 and blocks the interaction between the two cellular proteins; this
binding also increases the degradation of FADD and procaspase-8. Both events prevent
the successful completion of apoptosis, and cells become resistant to cell death induced
by TNF-, Fas-, and TRAIL [70, 75, 87].
Although two vaccines designed to prevent cervical cancer are now available
[97-99], the development of effective therapeutic drugs directed against HPV infection
and disease remains an urgent need. Because the vaccine is prophylactic rather than
therapeutic, it will bring no benefit to women and men who are already infected. In fact,
it will not have a significant effect on human health for decades, as most women become
infected in their late teens/early twenties, while cancer appears in their late forties/early
fifties. Furthermore, the vaccine targets only two of the high-risk strains (16 and 18),
which together account for 70–75% of the cases, leaving 25–30% of the high-risk
infections unaffected by an individual’s vaccination status. Finally, the high cost and
multiple boosters needed (three shots total) make it unlikely that this vaccine will become
readily available in the developing world in the near future.
For these reasons, the development of novel and effective therapeutic
interventions for established cases of cervical cancer remains an urgent need. Small
molecule approaches have been used to inhibit important signal transduction pathways
that are involved in breast, colon, pancreatic and lung cancer formation [78, 88].
However, such small molecule-based therapeutic agents have not yet been fully
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developed for HPV-mediated cancers. Our current knowledge of the molecular
mechanisms by which HPV 16 E6 prevents apoptosis through the extrinsic pathway [12,
70, 72, 87, 96] has now allowed us to propose a novel approach for using small
molecules to inhibit the binding between E6 and the key players of extrinsic apoptosis,
FADD and procaspase 8. If this binding can be prevented, cells should be resensitized to
apoptotic mediators such as TRAIL, and TRAIL-based therapy can then be successfully
used to initiate apoptosis of E6-expressing tumor cells. In this paper we report on our
results from screening a small molecule library for molecules that can prevent E6/FADD
and E6/caspase 8 binding. In this study, we used AlphaScreen™ technology (Perkin–
Elmer) to search for molecules capable of inhibiting E6/FADD and E6/caspase 8 binding.
Secondary screening allowed us to eliminate a number of molecules from consideration,
and suggested two classes of chemicals for further analysis. The best candidate was the
flavonol, myricetin, which served as a potent inhibitor of E6/caspase 8 binding and
helped to define the structure–activity relationship (SAR) of the ligands.

Experimental Methods and Results
The construction of the pGEX-E6 and pTriEx-Caspase-8 DED plasmids has been
reported [12]. Expression and purification of GSTE6, His-FADD and His-Caspase-8
DED were carried out as previously described [12, 74]. GST-tagged and His-tagged
proteins were diluted in GST dilution buffer (PBS pH 8.0, 5% glycerol, 2 mM DTT) and
His dilution buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 2 mM KCl, 5% glycerol, 2
mM DTT). Protein concentration was measured using Coomassie Plus—The Better
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Bradford Assay Reagent (Thermo Scientific). The purity of the isolated proteins was
estimated following separation by SDS–PAGE and Coomassie staining (Figure 1).
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Figure 1. Purity of isolated proteins. Purified proteins (10 ug) were separated by SDS–
PAGE. The gel was then stained using the Coomassie reagent. Lane 1: GST-E6, Lane 2:
GST-caspase 8, Lane 3: His-caspase 8.
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We began by using AlphaScreen™ technology to screen a 949 member smallmolecule library from TimTec, LLC (Newark, DE) designed for similarity to kinase
inhibitors. Members of the library were present at 10 μM in DMSO. Briefly, GST-E6 and
His-FADD proteins were purified from Escherichia coli lysates after induction of protein
expression by IPTG (Figure 1). 5 μl (1 ng) of GST-E6 and 5 μl (338 ng) of His-FADD
were included in each reaction mixture with 5 μl blocking buffer (0.5 mg BSA, 0.5%
Tween 20 in PBS) in the absence or presence of 10 μM of each test chemical. After a
one-hour incubation of the mixture at room temperature, 5 μl donor beads and 5 μl
acceptor beads (Perkin–Elmer) were added to each well according to the manufacturer’s
protocol. The mixture was incubated in the dark at room temperature overnight, and the
emitted signal was detected using the Envision Multilabel plate reader (Perkin–Elmer). In
the presence of test chemicals, the binding affinity was calculated as a percentage of the
binding in the presence of carrier only (DMSO). Of the 949 chemicals initially screened,
108 chemicals demonstrated some ability to interfere with E6 binding (11.4% of the
original set of chemicals). These chemicals were then re-tested in triplicate to confirm
activity, and 61 of the 108 showed some inhibitory activity (6.4% of the initial 949
chemicals). The compounds that demonstrated a high level of activity (inhibition of 90%
and higher) were tested again in triplicate at 1:10 and 1:100 dilutions (1 μM and 0.1 μM).
Finally, those compounds that appeared to show a dose–response relationship were
retested at 1:50 and 1:500 dilutions in triplicate.
To analyze this screening data, we began with a SD file of the structures and the
corresponding well layout provided by TimTec, LLC and imported it into an initial
ChemFinder 11.0 database. The database was then exported into a ChemOffice for Excel
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spreadsheet. The structures were reviewed, and from these structures, a series of physical
properties was calculated using the functions available in ChemOffice for Excel. These
properties were: (1) clogP:calculated log octanol/water partition coefficient; (2) number
of hydrogen bond donor atoms; (3) number of hydrogen bond acceptor atoms; (4) number
of rotating bonds; (5) polar surface area; (6) molar refractivity; (7) number of heavy
atoms.
From these data, another column assessed these parameters and the compounds
were judged as passing or failing the Lipinski Rule of Five [100]. The structures were
also assessed visually for possible reactivity with thiol groups (e.g., Michael acceptors),
as HPVE6 has 6 surface Cys thiol residues. Compounds that failed the Lipinski Rule of
Five, were not ‘lead-like’ [101] (100 < MW< 350 & 1 < clogP < 3) or were deemed
potentially thiol-reactive were removed from consideration. After testing and data
analysis we were left with 19 compounds from several different structural classes out of
the original 949 compounds in the library.
Among the most potent of the 19 were a flavonol, kaempferol, and a flavone,
chrysin 7-methyl ether. Notably, flavone and apigenin were in the original library and did
not exhibit sufficient potency for selection. These data indicate that this class of
compounds exhibits clear SAR at this binding site. Additionally, the literature contained
several descriptions of this class of compounds having potential antitumor activity [87,
102-105].
We had shown previously that the E6 binding motifs on FADD and procaspase 8
proteins have a similar structure, and that the E6 binding to FADD and to procaspase 8
can be blocked by the same blocking peptide in both in vivo and in vitro assays [74].
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Consistent with these findings, we were able to verify that kaempferol could indeed
inhibit both the His-FADD and His-caspase 8 interactions with GST-E6 in a dosedependent manner. Therefore, later analyzes were carried out using His-caspase 8 DED
rather than His-FADD. Two advantages for the change were: (1) the His-caspase 8 DED
protein proved easier to consistently purify than His-FADD as a properly folded protein,
therefore giving us greater consistency in our assay results, and; (2) using this assay
allowed us to perform analogous counter-screening to demonstrate specificity, by asking
whether candidate molecules did or did not inhibit the binding between His-caspase 8 and
GST-caspase 8.
To follow up on the flavone/flavonol hits, 19 flavones and flavonol compounds
representing systematic substitution of the ring system were selected and purchased, and
then tested for inhibition of the E6/caspase 8 interaction (Table 1). We sought to
determine the SAR for these ligands with regards to their binding to E6, and also asked
whether the SAR corresponded to the prior literature or was unique.

32

Table 1. Structures of the flavones and 3-flavonols tested for their ability to inhibit the
interaction between HPVE6 and caspase 8. Position numbers are given on the structure as
the superscript.
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AlphaScreen™ technology (Perkin–Elmer) was used to detect the interaction
between GST-E6 and His-caspase 8 using the same methodology and incubation times
described above. The binding reaction was performed in a 384-well plate format in a total
volume of 25 μl per well. Each well contained 5 μl GST-E6 protein (4.37 ng), 5 μl Hiscaspase 8 protein (50 ng), 5 μl blocking buffer (0.5 mg BSA, 0.5% Tween 20 in PBS), 5
μl chemical compounds at different concentrations diluted in PBS, and 5 μl of the
acceptor and donor beads solution.
The structural characteristics of tested flavones are presented in Table 1. Each of
these compounds was tested at four different concentrations, from 20 nM to 20 μM, and
the results demonstrated that six of them, including kaempferol, inhibited the interaction
between E6 and caspase 8. These data of relative potency gave the following ranking: 1 >
2 > 3 > 4 = 5>>(6–19). The structure– activity relationship (SAR) that these data suggest
are that the 3,5,7-OH groups are all important:
3-OH 4 > 6 5-OH 5 > 7 7-OH 3 > 8
and that in the prime ring hydroxyl groups affect potency:
3’, 4’, 5’ (1) > 2’,4’ (2) > 3’,4’ (3) > 4’ (4) = none (5)
3’-methoxy vs 3’-OH eliminates affinity (9 vs 3)
Additionally, we determined the IC50 for 1–5 and 13 (Fig. 2). For kaempferol and
quercetin the IC50 was greater than 20 μM, while for morin, 50% inhibition was achieved
at 4 μM. The compound with the lowest IC50 concentration was myricetin with an IC50
of approximately 850 nM.
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Figure 2. IC50 determination of selected compounds. The binding between GST-E6 and
His-caspase 8 DED was used to determine the IC50 of each test chemical. 4.37 ng of
GST-E6 and 50 ng His-caspase 8 were mixed in each well and the indicated
concentrations of the test chemicals were applied. Binding in the presence of DMSO only
was set at 100%. The p-values were < 0.05 when morin was compared to 6-hydroxy
flavonol, galangin, kaempferol, and quercetin at 40 μM and 13 μM, and to 6-hydroxy
flavonol, galangin, kaempferol, quercetin, and myricetin at 4 μM and 1.3 μM. The pvalues were <0.05 when myricetin was compared to 6-hydroxy flavonol, galangin,
kaempferol, quercetin, and morin at 40 μM, 13 μM, 4 μM and 1.3 μM. The p-values were
obtained by multiple comparisons using the Bonferroni correction [101].
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The mammalian two-hybrid system has previously been used to show that
caspase 8 binds to itself [87]. For this reason, we were able to use this system to
determine the specificity of the inhibitors, as compounds that inhibited the caspase
8/caspase 8 binding were likely to either interact with caspase 8 rather than E6, or to
influence the assay itself in a non-specific manner. Therefore, to determine whether the
observed inhibitions were indeed specific, or whether they might instead reflect some
nonspecific mechanism related to the assay method, candidate compounds were tested for
their ability to inhibit binding between GST-caspase 8 and His-caspase 8. As shown in
Figure 3, we found that myricetin, morin and 6-hydroxy flavonol exhibited no inhibition
of caspase 8/caspase binding over a range of concentrations.
The structure–activity relationship we observe for the inhibition of HPV16 E6
binding to caspase 8 is distinctly different from prior reports of flavones in a variety of in
vivo and in vitro anticancer assays [103-107]. The reducing environment of the assays,
the distinct SAR, and the specificity experiments all indicate that this is a real inhibition
by the flavonols and not a non-specific artifact from flavonol oxidation products.
Therefore, these results represent the first report of the potential of flavonols for the
prevention or reversal of HPV-induced apoptotic blockade. Preliminary in vivo studies
(data not reported here) indicate a weak ability for myricetin to suppress TRAIL induced
tumor growth. Poor cellular penetration is likely the reason for the modest result due to
the highly polar nature of the compound. Since the polar groups are an important feature
of the SAR, optimization of this series of compounds would be difficult without resorting
to a prodrug approach, further complicating the optimization process. Therefore, we are
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also engaged in additional screening efforts with libraries containing more ‘lead-like’
members that will enable optimization [108].
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Figure 3. Specificity of the inhibition of E6/caspase 8 binding. The ability of myricetin,
morin, and 6-hydroxy flavonol to inhibit binding between His-caspase 8 and either GSTE6 or GST-caspase 8 was assessed using the bead-based binding assay, as described in
the legend of Figure 2. Where indicated, 13.5 ng GST-caspase 8 was added to each well.
The p-values were <0.001 when myricetin and morin were compared to 6-hydroxy
flavonol only in GST-E6/His-caspase 8 group. The p-values were obtained by multiple
comparisons using the Bonferroni correction.
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CHAPTER THREE
FLAVONOL AND BENZIMIDAZOLE DERIVATIVES BLOCK HPV16 E6
FUNCTIONS AND REACTIVATE APOPTOSIS PATHWAYS IN HPV+ CELLS

Introduction
High-risk types of human papillomavirus (HPV), especially types 16 (species 9)
and 18 (species 7), are the causative agents of nearly all cases of human cervical cancer,
between 20% and 30% of head and neck cancer cases, and some cases of other cancers
(for example, vaginal and penile cancers) [109]. Cervical cancer is the second most
common cancer in women worldwide. Approximately 400,000 new cases of this disease
are diagnosed each year, and approximately half of these patients will die. HPV are small,
double stranded DNA viruses that infect epithelial tissues, including those of the
anogenital tract. The HPV-encoded oncogenes E6 and E7 are responsible for cellular
immortalization and transformation, and consequently, for the development of HPVassociated cancer. While E7 is best known for the inactivation of Rb and thus for the
immortalization of differentiated cells, E6 induces degradation of several molecules
involved in apoptosis.
Recently, two HPV vaccines, Gardasil (MSD) and Cervarix (GSK), have been
developed and approved for the prevention of infection with either two or four types of
HPV. These vaccines are therefore predicted to reduce the incidence of cervical cancer.
However, while these vaccines can prevent HPV infection, they offer no benefit to an
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individual who has already been infected with HPV. Also, the vaccines will not have a
significant effect on human health for decades, because most women are infected in their
late teens/early twenties, while cancer appears in their late forties/early fifties.
Furthermore, the vaccines only protect against HPV-16 and -18, leaving 25–30% of highrisk infections unaffected by an individual’s vaccination status. An additional issue is the
high cost of these vaccines, making it difficult to deliver them to areas and populations
with low resources.
Surgical treatment is often employed to cure cervical cancer in the early stages.
However, it can be difficult to apply this approach to head and neck cancers or to
laryngeal papillomatosis, due to the need to maintain the normal structure of the airway
and to avoid pulmonary spread. Furthermore, even following surgical excision, HPVassociated cancers frequently return, especially in the immunocompromised population.
Combined chemoradiotherapies have been assessed, with variable results [110]. Topical
treatments, such as trichloroacetic acid, liquid nitrogen, imiquimod, interferon-
injections and podophyllin resin, are also available [11, 111-113]. However, repeated
treatments are necessary and are not always effective. Furthermore, imiquimod has not
been approved for use in the oral cavity. Even when a wart or papilloma can be removed
by such approaches, the HPV infection has not necessarily been cured and may return. In
conclusion, there is no effective antiviral agent currently available.
Most currently employed chemotherapies, such as cisplatin and doxorubicin,
focus on activation of the intrinsic (p53-mediated) apoptosis pathway. Cisplatin has been
used for cancer treatment since 1978, and is considered the most active single agent for
the treatment of cervical cancer [114-116]. Cisplatin carries a positive charge when
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entering cells, and binds to nucleophilic molecules such as DNA, RNA, and proteins. By
interacting with DNA and forming adducts, cisplatin blocks DNA replication and causes
DNA damage, p53 expression, and apoptosis. Doxorubicin was first discovered as an
anthracycline antibiotic, and has been used as chemotherapy drug to treat many different
cancers [117]. The mechanism of action proposed for doxorubicin is that it can intercalate
into the DNA molecules, thus causing the inhibition of topoisomerase-II, DNA damage,
and p53 up-regulation during DNA replication [118].
On the other hand, activation of the TRAIL-mediated, extrinsic apoptotic
pathway shows promise in the treatment of several types of tumors. These therapies have
elicited significant interest in recent years, largely due to their apparent ability to kill
tumor cells while sparing most normal cells. TRAIL receptors 1 and 2 (TRAIL R1 and
TRAIL R2, also known as DR4 and DR5, respectively) are highly expressed on a large
number of solid and hematologic cancers, and many of these tumors are sensitive to the
induction of apoptosis induced by both TRAIL itself and by antibodies to the receptor [83,
119-123]. Previous studies have reported on the effectiveness of both TRAIL and TRAIL R1 and R2 in combination with other sensitizing agents such as doxorubicin,
bortezomib, adriamcin, 5-fluorouracil, irinotecan hydrochloride, paclitaxel, carboplatin,
gemcitabine, cisplatin and radiation in both cell and animal model systems [83-86]. Initial
data suggests that this antibody is well tolerated, has a half-life of 13-19 days, and in
some patients, is associated with a reduction in tumor size [124, 125].
Unfortunately, therapies that function by activating apoptosis, including those
based on p53 or TRAIL, are unlikely to effectively treat HPV-associated malignancies, as
high-risk E6 proteins subvert both extrinsic and intrinsic apoptotic pathways. E6 proteins
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from high-risk types of human papillomavirus, such as HPV 16 and HPV 18, are well
known for their ability to mediate the rapid degradation of p53, a tumor suppressor that
engages the intrinsic apoptotic pathway [61, 126, 127]. The p53 tumor suppressor is the
first-described and best-known target of HPV E6 [61]. p53 acts as a transcriptional factor,
and can trigger cell cycle arrest or apoptosis in response to cellular stress or DNA
damage. Under normal conditions, triggers such as DNA damage cause increases in the
level of p53, which then lead to downstream effects such as cell cycle arrest and/or
apoptosis, depending on the intensity or amplitude of the damage or stimulus. The
presence of E6 from high-risk types of HPV interferes with this process, because E6
binds to both p53 and E6-associated protein ligase (E6AP), causing ubiquitinylation and
the subsequent degradation of p53. This loss then prevents p53 from inducing either
growth arrest or apoptosis of infected cells [62]. This E6-mediated inhibition of p53
activity can therefore increase the survival of transformed cells [63, 64]. Interestingly, a
recent study showed that E6 could also interact with ubiquitin ligases other than E6AP in
order to promote p53 degradation [65]. In addition to p53, E6 also interacts with other
partner proteins that play a variety of roles in the cell. Our laboratory has discovered that
HPV 16 E6 also blocks engagement of the extrinsic, receptor-mediated apoptotic
pathways by binding to and inactivating several molecules involved in these signaling
complexes, including TNF R1 [128], FADD [129] and caspase 8 [130]. For example, our
lab has shown that HPV 16 E6 can protect HCT116 cells from apoptosis triggered by
TRAIL by accelerating the degradation of both FADD and caspase 8 [131]. As a result of
these E6 activities, therefore, engagement of either the extrinsic or the intrinsic apoptotic
pathways does not result in the transduction of the intended death signal because the
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mediator molecules – p53 in the case of the intrinsic pathway, and FADD and caspase 8
in the case of the extrinsic pathway – are missing. Therefore, if any of these apoptosisinducing signaling pathways are to be used as tools for the elimination of HPV-associated
malignancies, it will be necessary to restore the missing signaling molecules.
In our previous work [89], we identified myricetin as a compound that can inhibit
the E6/caspase 8 interaction. Unfortunately, myricetin is known to also inhibit number of
cellular proteins, including several tyrosine kinases, and its structure makes modification
difficult. Furthermore, our laboratory found that myricetin has a much lower efficiency in
a cell-based system than in in vitro, suggesting difficulty in entering cells. Therefore, the
identification of additional, more tractable inhibitors of E6 /procaspase 8 interaction is
necessary.
In this study, we proposed to begin overcoming this challenge by identifying one
or more additional small molecules that can inhibit HPV E6 function and re-sensitize
HPV+ cells to apoptosis. Screening an ActiPribe 2K library enabled us to identify
benzimadole derivatives as a class of interest, and we further examined the ability of one
particular derivative, 6,7-Dihydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid (DIPC),
to inhibit specific interactions between E6 and its partner proteins. We found that DIPC
was able to block E6 binding to both E6AP and to caspase 8 in vitro with IC50 values of
20 μM and 17 μM, respectively. Within cells, we found that DIPC, as well as the flavonol
myricetin, can re-sensitize HPV+ cells to apoptosis triggered by apoptotic inducers such
as TRAIL, cisplatin, and doxorubicin. Furthermore, we found that both DIPC and
myricetin could also increase caspase 3/7 activity and restore the level of apoptotic
proteins in HPV+ cells. These findings identify a novel small molecule that can inhibit E6
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functions, and may serve as the basis for further discovery and development of effective
and novel therapeutic approaches for the treatment of cervical cancer.

Materials and Methods
Protein Purification
The construction of the pGEX-E6, pTriEx-E6AP, and pTriEx-Caspase-8 DED
plasmids has been reported [12]. Expression and purification of GSTE6, His-E6AP, and
His-Caspase-8 DED were carried out as previously described [12, 74]. GST-tagged and
His-tagged proteins were diluted into GST dilution buffer (PBS pH 8.0, 5% glycerol, 2
mM DTT) and His dilution buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 2 mMKCl, 5%
glycerol, 2 mM DTT), respectively. Protein concentration was measured using
Coomassie Plus—The Better Bradford Assay Reagent (Thermo Scientific). The purity of
the isolated proteins was estimated following separation by SDS–PAGE and Coomassie
staining.

Small Molecule Library and Acquisition of Additional Compounds
The 2,000-compound small molecule library (ActiProbe 2K) from TimTec, LLC
(Newark, DE) was to encompass a highly diverse selection of lead-like compounds. Five
additional benzimidazole derivatives were purchased from Sigma (Benzimidazole, 2(methoxymethyl)-1H-benzimidazole, and

3-(1H-Indol-1-yl)propan-1-amine

methanesulfonate) and TimTec (1H-benzimidazole-1-methanol and 6,7-Dihydro-1Himidazo[4,5-c]pyridine-6-carboxylic acid)
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Screening of Small Molecular Library
Alpha-ScreenTM technology was used to assess the interactions between GST-E6,
His-E6AP, and His-caspase 8. Binding assays were performed in white 384-well plates
(Perkin-Elmer) in a total volume of 25 l as previously described [12]. Briefly, 5 l (50
ng) of GST-E6 and 5 l (87.5 ng) of His-caspase 8 were included in each reaction
mixture with 5 l blocking buffer (0.5 mg BSA, 0.5% Tween 20 in PBS) in the absence
or presence of 10 M of each test chemical. Members of the library were present at 10
M in DMSO. After a one-hour incubation of the mixture at room temperature, 5 l
donor beads and 5 l acceptor beads (Perkin–Elmer) were added to each well according
to the manufacturer’s protocol. The mixture was incubated in the dark at room
temperature overnight, and the emitted signal was detected using the Envision Multilabel
plate reader (Perkin–Elmer). In the presence of test chemicals, the binding affinity was
calculated as a percentage of the binding in the presence of carrier only (DMSO).

Cell Culture
U2OS, SiHa and C33A cells were obtained from the America Type Culture
Collection (Manassas, VA) and cultured in Eagle minimal essential medium (Invitrogen,
Carlsbad, CA) supplemented as described previously [12].

Cell Viability Assay
To measure cell survival after treatment with TRAIL and chemotherapy drugs,
SiHa (2x104/well) and C33A (1x104/well) cells were seeded into 96-well plates and
allowed to adhere overnight. Small molecules at the desired concentration were added
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and incubated at 37oC for 4 h. TRAIL, cisplatin or doxorubicin was then added in the
presence of cycloheximide (5 g/ml) to inhibit de novo protein synthesis, and the cells
were incubated for 16 h prior to measuring cell viability by the MTT assay preformed as
described previously [70].
Caspase Activity Assay
Cells were plated into 96-well plates at a density of 2×104 cells per well and
incubated overnight. Small molecules were added and incubated at 37 oC for 4 h. TRAIL
(100 ng/ml) was then added, along with cycloheximide (5 μg/ml) at the indicated time
points. Caspase 3/7 activity was measured using the flourogenic substrate CellTitier-Glo
for caspase 3/7 activity (Promega) following the manufacturer's instructions. Briefly,
cells were lysed by the addition of 20

l of 5X passive lysis buffer (Promega). The plate

was put on an orbital shaker and incubated for 10 min at room temperature. 20 l of cell
lysates were transferred to white plates, and either substrate alone or substrate plus the
caspase 3/7 inhibitor was added to the appropriate wells. After 10 min incubation, the
released fluorophore was measured using a plate-reading fluorimeter (Flx800, Bio-Tek
Instrument Co). The activity in wells treated with inhibitor was subtracted from the
activity in wells lacking inhibitor. The resulting difference was expressed as a percentage
of the caspase activity of the untreated cells.

Results
Benzimidazole Derivatives Specifically Inhibit the Interaction of HPV
E6 with Caspase 8
Previously, we have reported that HPV E6 binds to caspase 8 [72] and that
myricetin can block the E6/caspase 8 interaction in vitro [89]. In this study, we screened
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the ActiProbe 2K (2,000 compounds) library, using AlphaScreenTM technology from
Perkin-Elmer, to look for inhibitors of the E6/caspase interaction. In our primary screen,
118 (5.9%) compounds demonstrated an ability to inhibit the E6/caspase 8 interaction. 79
of these 118 compounds presented IC50 values lower than 10

M, and were therefore

chosen for further experiments. 23 out of these 79 compounds also demonstrated specific
inhibition of the E6/caspase 8 interaction, in that they were unable to block formation of
the caspase 8/caspase 8 homodimer (counter-screen). These 23 compounds represented
three different chemical classes, of which the benzimidazoles showed the best inhibition
of E6/caspase 8 binding. Analysis of the structures and physical/chemical characteristics
of those molecules led to the selection of five additional benzimidazole derivatives which
were then purchased from Sigma and TimTec (Benzimidazole, 2-(methoxymethyl)-1Hbenzimidazole, and 3-(1H-Indol-1-yl)propan-1-amine methanesulfonate were purchased
from Sigma; 1H-benzimidazole-1-methanol and 6,7-Dihydro-1H-imidazo[4,5-c]pyridine6-carboxylic acid were purchased from TimTec) (Figure 1).
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Figure 1. Five analyzed benzimidazole derivatives (A) Benzimidazole (B) 2(methoxymethyl)-1H-benzimidazole
(C)
3-(1H-Indol-1-yl)propan-1-amine
methanesulfonate (D) 1H-benzimidazole-1-methanol (E).6,7-Dihydro-1H-imidazo[4,5c]pyridine-6-carboxylic acid
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To determine the dose-responsiveness of these five compounds, variable
concentrations of those small molecules were first tested for their ability to inhibit
E6/caspase binding. The results showed that both 3-(1H-Indol-1-yl)propan-1-amine
methanesulfonate and 6,7-Dihydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid (DIPC)
demonstrated dose-dependent inhibition of E6/caspase 8 binding (Figure 2A). We then
asked whether these molecules, which had been selected for their ability to interfere with
E6/caspase 8 binding, could also affect other interactions of E6, such as its binding to
E6AP. Inhibition of one or more of these additional E6 interactions has the potential to
enhance the therapeutic effectiveness of agents developed from those chemical
compounds. The E6/E6AP interaction has been studied extensively, and is required for
the E6-mediated acceleration of p53 degradation. We therefore tested the ability of these
five benzimidazole derivatives to inhibit E6/E6AP binding, and found that both 3-(1HIndol-1-yl)propan-1-amine methanesulfonate and DIPC, the same two agents that had
inhibited E6/caspase 8 binding, could also inhibit the E6/E6AP interaction and could do
so nearly as well as they had inhibited the E6/caspase 8 interaction (Figure 2B). To ask
whether this inhibition was specific, we employed a counter-screening assay in which we
assessed the ability of candidates to inhibit the binding of GST-caspase 8 to His-caspase
8; those that did were to be eliminated. In this counter-screening assay, the materials in
each well were the same as in the primary screen with the exception that GST-caspase 8
replaced GST-E6. 3-(1H-Indol-1-yl)propan-1-amine methanesulfonate was able to inhibit
the caspase 8/caspase 8 interaction about as well as it inhibited the E6/caspase 8
interaction, indicating that its action was non-specific. However, DIPC did not
significantly inhibit the binding of caspase 8 to itself, providing evidence of its specificity
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for E6 (Figure 2C). These results are summarized in Table 1, which shows that of the
compounds tested, DIPC displayed the lowest IC50 value for the inhibition of E6/caspase
8 and E6/E6AP interactions, but did not inhibit caspase 8/caspase 8 binding.
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Figure 2. Benzimidazole derivatives inhibit protein-protein interactions.
Five compounds, at the indicated concentrations (1.4 uM to 3.2 uM) were
tested for their ability to inhibit three different protein/protein interactions: (A)
GST-E6/His-caspase 8 (B) GST-E6/HisE6AP
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Figure 2 continued. (C) GST-caspase 8/His-caspase 8. Binding in the presence
of DMSO only was set at 100%. Experiments were performed in triplicate, and
error bars indicate the standard deviation.
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Table 1. The IC50 values of tested small molecules for the indicated protein-protein
interactions.
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Myricetin and DIPC Sensitize SiHa Cells to TRAIL-Induced
Apoptosis
Following identification of molecules that can block E6/caspase 8 binding in vitro,
the next step was to determine which of these molecules could also act in the context of a
cell. SiHa cells are an HPV+ cell line, derived from a cervical carcinoma, that serves as a
commonly-used model for HPV-associated malignancies. SiHa cells are resistant to
TRAIL-induced apoptosis as a result of their expression of HPV E6 (Figure 3). In this
experiment, U2OS cells display the TRAIL-sensitive phenotype. We selected 1Hbenzimidazole-1-methanol, which showed no inhibition in vitro (Table 1), as our
negative control.

54

120

% Viability

100
80
60

Siha

40

U2OS

20
0
0

0.38 1.53 6.125 25 100
TRAIL concentration (ng/ml)

Figure 3. HPV+ SiHa cells are resistant to TRAIL-induced apoptosis as compared
to the human osteosarcoma cell line U2OS. The viability of cells untreated with
TRAIL was set at 100% for each group. Experiments were performed in triplicate,
and error bars indicate the standard deviation.
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We first determined the non-specific toxicity of our small molecules of interest.
SiHa cells were treated with several concentrations of these molecules (0

M, 15.6 M,

31 M, 62.5 M, and 125 M) for 16 hours, and cell viability was assessed using the
MTT assay. A loss of viability of about 20%-30% following treatment with 62.5 M for
16 h was observed with all compounds (Figure 4A). We next asked whether myricetin
and DIPC would be able to sensitize HPV+ cells to TRAIL, an inducer of extrinsic
apoptosis. SiHa cells (2x104 per well) in culture were seeded into a 96-well plate for
overnight incubation. The indicated concentrations (0 M to 125 M) of myricetin, 1Hbenzimidazole-1-methanol, and DIPC were then added to the appropriate wells, and the
cells allowed to pre-incubate for 4 hours. Next, cells were treated with cycloheximide

Cell death was measured using the MTT assay. Both myricetin and DIPC induced
significantly more cell death (an increase of 3.5 fold for myricetin and 8.6 fold for DIPC)
in combination with TRAIL (Figure 4B) (Table 2). These results provide strong evidence
that inhibiting the E6/caspase 8 interaction can restore the sensitivity of HPV-positive
cells to apoptotic signals.
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Figure 4. (A) Both myricetin and DIPC display low toxicity, with a viability loss
of approximately 20% observed following treatment with 62.5 μM of either
compound. (B) The addition of either myricetin or DIPC re-sensitizes these
HPV+ cells to TRAIL, inducing a loss of viability of more than 40% following
treatment with 62.5μM of either compound. Experiments were performed in
triplicate, and error bars indicate the standard deviation.
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Table 2. The IC50 value of the indicated compounds for cell toxicity and for TRAILinduced apoptosis.
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Myricetin and DIPC Increase the Sensitivity of SiHa Cells to
Doxorubicin and Cisplatin
As noted earlier, both myricetin and DIPC can inhibit the binding of E6 to E6AP,
an E3 ligase involved in the degradation of p53, in vitro, One prediction stemming from
this observation is that these two chemicals should increase the sensitivity of SiHa cells
to chemotherapy drugs that act through the p53 pathway. To test this prediction, we asked
whether myricetin and/or DIPC would increase the sensitivity of SiHa cells to two such
drugs, doxorubicin and cisplatin. SihH cells (2 x 104 per well) were seeded into a 96-well
plate. After overnight incubation, 100 μM myricetin or 50 M DIPC were added to the
indicated groups, and cells allowed to incubate for 4 hours. The indicated concentrations
of doxorubicin (0-10 M) and cisplatin (0-100 M) were then added for a 16-hour
treatment, and cell death was assessed using the MTT assay. As compared to the negative
control, myricetin increased the sensitivity of SiHa cells to doxorubicin and cisplatin by
approximately 20-30% (Figure 5A). DIPC displayed a similar effect, in that it increased
the sensitivity by approximately 30-40% (Figure 5B). These results demonstrate that both
myricetin and DIPC can inhibit the interaction between E6 and E6AP within cells, thus
reducing the degradation of p53 and increasing the sensitivity of HPV+ cells to inducers
of p53-mediated apoptosis.
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Figure 5. Myricetin and DIPC increase the sensitivity of SiHa cells to
chemotherapy drugs. Pretreatment with either myricetin or DIPC increases the
sensitivity of SiHa cell to doxorubicin (A) and cisplatin (B) by approximately
20% (DIPC) to 30% (myricetin). The viability of cells untreated with either
myricetin or DIPC was set at 100%. Experiments were performed in triplicate,
and error bars indicate the standard deviation.
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Myricetin and DIPC Re-sensitize HPV+ Cells to TRAIL-Induced
Apoptosis by Blocking the Binding of HPV E6 to Caspase 8
To determine whether myricetin and DIPC re-sensitize SiHa cells to TRAILinduced apoptosis by specifically blocking the binding of E6 to caspase 8 or through
some other mechanism, we chose to employ the HPV- human cervical carcinoma cell,
C33A, for comparison, as these cells do not express E6. Both SiHa and C33A cells were
either left untreated or pre-treated with either myricetin (100 M) or DIPC (50 M) for 4
hours, then treated with cycloheximide plus TRAIL (0-100 ng/ml) for 16 hours. Cell
death was measured using the MTT assay. Although the HPV+ SiHa cells displayed
resistance to TRAIL at concentrations up through 100 ng/ml, their sensitivity increased
dramatically in the presence of 100 M myricetin. In contrast, the HPV- C33A cells
remained resistant to TRAIL-mediated apoptosis even in the presence of myricetin
(Figure 6A). Similar results were also found following pre-treatment with 50 M DIPC
(Figure 6B). Together, these results demonstrate that myricetin and DIPC can re-sensitize
HPV+ cells to TRAIL-mediated apoptosis by specifically blocking the binding of HPV
E6 to apoptotic proteins such as caspase 8, but likely not through other apoptotic
mechanisms.
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A

B

Figure 6. Myricetin and DIPC can re-sensitize HPV+, but not HPV-, cells to
treatment with TRAIL. Pre-treatment with myricetin resulted in an 80% loss of
cell viability (A) while pre-treatment with DIPC caused a 60% loss of cell
viability (B) in SiHa cells treated with 100 ng/ml TRAIL. No significant
decrease in cell viability was observed in C33A cells or in the absence of
myricetin/DIPC. The viability of cells untreated with TRAIL was set as 100%
for each group. Experiments were performed in triplicate, and error bars
indicate the standard deviation.
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Myricetin and DIPC Increase Caspase 3/7 Activity
Activation of caspase 3/7 is an essential marker for both extrinsic and intrinsic
apoptosis, and can be used to determine whether the increase in cell death observed when
TRAIL, cisplatin or doxorubicin combined with myricetin or DIPC indeed occurs
through the apoptotic pathway. Our previously described data (Figure 2) demonstrates
that both myricetin and DIPC can inhibit the E6/caspase 8 and E6/E6AP interactions in
vitro. One prediction following from this data is that pre-treatment with either myricetin
or DIPC should increase the level of TRAIL-, cisplatin- and doxorubicin-induced
activation of caspase 3/7. To test this prediction, caspase 3/7 activity was measured in
SiHa cells following TRAIL, cisplatin or doxorubicin treatment in the presence or
absence of myricetin or DIPC. As shown in Figure 7A, we found that the caspase 3/7
activity increased approximately 2 fold when myricetin or DIPC were combined with
TRAIL as compared to cells not exposed to myricetin or DIPC. Similar results were
obtained following treatment with cisplatin and doxorubicin (Figure 7B, 7C). These data
demonstrate that the increased cell death induced by the combination of apoptotic
inducers and myricetin/DIPC occurs through the apoptotic pathway.
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Figure 7. Myricetin and DIPC increase caspase 3/7 activity of SiHa cells after
TRAIL and chemotherapy drugs treatment. SiHa cells were pre-treated with
myricetin or DIPC 4 hours prior to application of the indicated inducers of apoptosis.
100 ng/ml TRAIL (A), 50
M cisplatin (B), or 2
M doxorubicin (C) were added
as indicated, and caspase 3/7 activity was measured after 0, 1.5, 3, and 6 hours.
Activity at 0 h of treatment was set at 100% for each group. Experiments were
performed in triplicate, and error bars indicate the standard deviation.

64

Discussion
Currently, no small molecules targeting any of the HPV proteins are available for
clinical use. However, a number of groups are currently examining the possibility of
developing these sorts of small, inhibitory molecules in order to expand and enhance the
limited therapeutic options currently available for HPV-associated malignancies [78, 132].
HPV E1 and E2 are enzymes involved in replication and gene expression, and thus were
some of the initial targets for the development of small, inhibitory molecules. As one
example, biphenylsulfonacetic acid has been shown to inhibit E1 ATPase activity, and
the optimized compound has an IC50 value of 4.0 nM [133]. However, E1 and E2 are
often lost during the development of cancer, making them less-than-optimal targets for
cancer treatment. In contrast, E6 and E7 oncogenes are expressed at relatively high levels
during cancer development and therefore have the potential to serve as useful targets for
small molecule inhibitors. For example, inhibition of E6 is predicted to lead to more cell
death, as E6 normally functions to block both intrinsic and extrinsic apoptotic pathways.
The prevention of E6-mediated p53 degradation, perhaps by inhibiting formation of the
E6/E6AP complex, represents one promising approach for the development of small
molecule inhibitors of HPV-associated cancer [134]. Previous studies have identified
several compounds that could inhibit the interaction between E6 and E6AP, thus reducing
the degradation of p53 [78, 79]. However, these findings have not yet led to clinically
useful interventions.
Therapies based on TRAIL-mediated apoptosis are attractive possibilities for the
treatment of many different types of cancer., For example, previous studies have
demonstrated the effectiveness of both TRAIL and
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-TRAIL R1 and R2 in combination

with other sensitizing agents such as doxorubicin, bortezomib, adriamcin, 5-fluorouracil,
irinotecan hydrochloride, paclitaxel, carboplatin, gemcitabine, cisplatin and radiation in
both cell and animal model systems to treat a variety of cancers [83-86]. However, these
treatments are unlikely to be helpful in the context of HPV on their own, due to the
ability of E6 to compromise apoptotic pathways. The studies described here, focused on
the identification of E6-inhibitory molecules, have the potential to make this type of
therapy available to patients suffering from HPV-associated malignancies. It is the first
reported that our study demonstrated the combination of TRAIL with small molecules
could re-sensitize E6-expressing cells to TRAIL-induced apoptosis.
Our laboratory previously reported that the flavonol myricetin can inhibit
interactions between E6 and caspase 8 in vitro. We confirmed this binding, and
demonstrated a direct interaction between E6 and myricetin by isothermal titration
calorimetry (ITC), an approach that can detect and characterize protein-protein and
protein-molecular interactions. Preliminary results (data not shown) indicate that
myricetin binds to E6 at a ratio of 1:1 (one molecule of myricetin to one molecule of E6).
Unfortunately, myricetin is known to inhibit a number of cellular proteins (including
several kinases), and in addition, the high IC50 value observed in the context of a cellbased model system (Table 2) suggested that its ability to negatively affect tumors may
be limited. Because the compound is highly polar, difficulty in entering cells may be the
explanation for these modest results. Since polar groups are an important feature in
assessing structure-activity relationships (SAR), optimization of this series of compounds
would be difficult without resorting to a pro-drug approach, further complicating the
optimization process. Therefore, we engaged in additional screening efforts with libraries
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containing more ‘lead-like’ members that are expected to provide better platforms for
optimization. This effort identified the benzimidazole family as a chemical group of
interest for drug development. Benzimidazoles are a large chemical family, and several of
these compounds have already been employed for medicinal chemistry due to their
various bioactivities. The core structure of benzimidazole is a heterocyclic ring (Figure 1),
and these compounds display a broad range of pharmacological effects, bioactivities, and
functions that are dependent on the functional groups that surround this core structure.
Previously, benzimadoles have been identified as useful for their antifungal, antioxidant
[135], antiallergic [136], and antimicrobial [137-139] properties. In recent years, they
were also found to display antitumor [140] and antiviral activities against HCV (Hepatitis
C Virus) [141] and HIV (Human Immunodeficiency Virus) [142].
Of the five tested benzimidazole derivatives, 6,7-Dihydro-1H-imidazo[4,5c]pyridine-6- carboxylic acid (DIPC) was best able to specifically inhibit the interactions
of E6 with both caspase 8 and E6AP (Figure 2), demonstrating the lowest IC50 values for
both E6/Caspase 8 and E6/E6AP binding. However, it did not inhibit Caspase 8/Caspase
8 binding, thus demonstrating the desired specificity (Table 1). To characterize the ability
of DIPC, as well as myricetin, to function within cells, the ability of the two chemicals to
cause cell toxicity and to enhance TRAIL-induced apoptosis were tested in the HPV+
SiHa cell line. The IC50 values of 154.8 μM for myricetin and 31.2 μM for DIPC,
respectively, demonstrate that myricetin in combination with TRAIL is approximately 3.5
fold as toxic as myricetin alone, while DIPC in combination with TRAIL is
approximately 8.6 fold as toxic as DIPC alone (Table 2). These results indicate that, as
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compared to myricetin, DIPC may be better able to penetrate into cells and thus resensitize cells more efficiently to TRAIL-induced apoptosis.
As mentioned previously, the interaction between E6 and E6AP accelerates
degradation of p53, a mediator of intrinsic apoptosis. Our in vitro results demonstrated
that DIPC could inhibit the interaction between E6 and E6AP, and thus has the potential
to increase the sensitivity of HPV+ cells to intrinsic apoptosis triggered by chemotherapy
drugs such as doxorubicin and cisplatin. This may be clinically relevant, because cervical
cancer tends to be relatively resistant to chemotherapeutic treatments such as cisplatin.
When we combined myricetin or DIPC with those chemotherapy drugs, we observed a
loss of cell viability of more than 30% as compared to that seen in the absence of these
sensitizing agents, indicating that indeed, myricetin and DIPC can both increase the
sensitivity of HPV+ cells to chemotherapy drugs that work through the p53 pathway.
Interestingly, DIPC appeared to be somewhat more effective than myricetin when
combined with TRAIL, while myricetin appeared more effective than DIPC when
combined with either cisplatin or doxorubicin. However, we note that myricetin required
the presence of a higher concentration (100 M) than did DIPC (50 M) to cause
inhibition of binding. Thus, we suggest that DIPC may actually demonstrate a higher
efficiency in sensitizing HPV+ cells to both TRAIL- and p53-mediated apoptosis.
Although we began by searching for inhibitors of extrinsic apoptosis, we found
that DIPC was able to block the binding of E6 to both caspase 8 and to E6AP, and thus
sensitize HPV+ cells to both extrinsic and intrinsic apoptosis. This may suggest a mode of
action in which the small molecule interacts directly with E6, either destabilizing the
virus protein and changing its conformation, or blocking the interactions by direct
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interference. If the latter, one possibility is that DIPC binds to a region on E6 required by
both E6AP and caspase 8.
In order to determine whether myricetin and DIPC re-sensitize cells to TRAILinduced apoptosis by specifically blocking the binding of HPV E6 to caspase 8, C33A, a
HPV- cell line that does not express E6, was compared to SiHa. Each cell line was
untreated or pre-treated with myricetin or DIPC, then different concentrations of TRAIL
were added and cell viability was measured after overnight incubation. Figure 6
demonstrates that SiHa cells pretreated with either myricetin or DIPC showed a greater
loss of cell viability than did the other groups. These results indicate that TRAIL-induced
apoptosis in SiHa was restored due to the ability of myricetin and DIPC to inhibit the
E6/caspase 8 interaction.
Finally, caspase 3/7 activity was assessed to determine whether the loss of cell
viability occurred through activation of the apoptotic pathway. Caspase 3/7 can be
activated through both the extrinsic and intrinsic apoptosis pathways, as induced by
TRAIL or chemotherapy drugs, respectively. We found that both TRAIL and
chemotherapy drug treatment, in combination with myricetin or DIPC, led to a significant
and enhanced time-dependent activation of caspase 3/7 activity in SiHa cells (Figure 7).
Taken together, these data indicate that myricetin and DIPC can block the binding of E6
to multiple apoptotic proteins, including caspase 8 and E6AP/p53, thereby reactivating
the E6-compromised apoptotic pathways and rendering HPV+ cells sensitive to both
intrinsic and extrinsic inducers of apoptosis. These activities suggest that myricetin and
DIPC may be able to inhibit multiple functions of E6, and therefore provide the basis for
developing an effective therapeutic strategy to treat HPV-mediated cancers.
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Overall, this study identified a new candidate, the benzimidazole derivative
DIPC, which effectively blocks the interactions of E6 with apoptotic proteins such as
caspase 8 and E6AP. Furthermore, both DIPC and myricetin were able to re-sensitize the
HPV+ cell line SiHa, but not the HPV- cell line C33A, to TRAIL-induced apoptosis,
indicating that they most likely work by blocking the binding between E6 and its
apoptotic protein partners. In addition to re-sensitizing HPV+ cells to TRAIL-induced
apoptosis, DIPC and myricetin could also increase the sensitivity of SiHa cells to two
chemotherapy drugs, doxorubicin and cisplatin, by blocking the E6/E6AP interaction and
restoring the level of p53. The observed increase in caspase 3/7 activity also provides
evidence that sensitization of SiHa cells by DIPC occurred through activation of
apoptosis.
Previous work from our laboratory had identified peptide inhibitors that can
specifically inhibit the interactions between E6 and caspase 8 and FADD, but not the
interaction between E6 and E6AP [12]. In contrast, both myricetin and DIPC inhibit the
interactions of E6 with both the caspase 8 and E6AP protein partners. As compared to
peptide inhibitors, small molecules such as DIPC have numerous advantages because
they are more stable, penetrate target cells more easily, and can be modified and
optimized by organic chemists during drug development. Because DIPC has the potential
to restore both the intrinsic and extrinsic apoptotic pathways, it may prove to be an ideal
candidate for making apoptosis-inducing therapies available to patients suffering from
HPV-associated malignancies.
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CHAPTER FOUR
DISSCUSION

Summary of Findings
High-risk strains of human papillomavirus (HPV), especially types 16 and 18, are
the causative agents of nearly all cases of human cervical cancer (approximately 400,000
new cases each year, with a 50% mortality rate), between 20% and 30% of head and neck
cancer cases, and some cases of other cancers (for example, vaginal and penile cancers)
[109]. Current treatment options are frequently inadequate, providing a sense of urgency
to the development of better, more effective clinical interventions.
The experiments described in chapter 2 demonstrate that myricetin, a flavonol,
can block HPV E6 interactions in vitro. To ask whether this inhibition was specific, we
developed a counter-screening assay in which we assessed the ability of candidates to
inhibit the binding of GST-caspase 8 to His-caspase 8; those that did were to be
eliminated. In this counter-screen, myricetin showed no inhibition to the binding of
caspase 8 to itself, providing evidence of its specificity for E6. These promising results
demonstrated that, indeed, small molecules capable of blocking E6/caspase 8 binding in a
specific manner existed, and that our bead-based assay could find them.
The results of experiments from chapter 3 identified a new class of chemicals,
benzimidazoles, which also showed the potential to block the binding of E6 to both
caspase 8 and E6AP. Since myricetin is not a suitable candidate for drug development
due to its inhibition of a number of cellular proteins as well as inherent difficulties in
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optimizing its structure, the identification of other inhibitors of E6/caspase 8 was deemed
to be necessary. Following the testing of five benzimidazole derivatives for dosedependency and specificity, we found that 6,7-Dihydro-1H-imidazo[4,5-c]pyridine-6carboxylic acid (DIPC) showed the greatest ability to inhibit both E6/caspase 8 and
E6/E6AP interactions while not blocking the binding of caspase 8 to itself, thereby
demonstrating both specificity for E6 and the ability to inhibit multiple E6 interactions.
Next, we performed a cell-based analysis designed to determine which of our
small molecules of interest could function well within cells. SiHa cells are a cervical
cancer cell line that maintains the entire genome of HPV and expresses E6, and therefore
functions well as a model system. We found that, as expected, SiHa cells are resistant to
TRAIL at concentrations up to 100 ng/ml. We also found that neither myricetin nor DIPC
were significantly toxic to SiHa cells. However, when TRAIL was combined with either
myricetin or DIPC, we observed a significant loss of cell viability (up to 50%), indicating
that both myricetin and DIPC are able to re-sensitize HPV+ cells to TRAIL-induced
apoptosis, DIPC more efficiently than myricetin. A comparison between SiHa and C33A
cells demonstrated that re-sensitization to TRAIL-induced apoptosis was due to specific
blocking of the binding of E6 to caspase 8, as no sensitization of C33A cells was
observed. In addition to its inhibition of E6/caspase 8 binding, DIPC was also able to
inhibit E6/E6AP binding, an interaction involved in p53 degradation. Myricetin and
DIPC increased the sensitivity of SiHa to the chemotherapy drugs doxorubicin and
cisplatin, agents that can induce p53-mediated apoptosis, consistent with the prediction
from our in vitro data. Finally, the increase of caspase 3/7 activity in both TRAIL- and
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chemotherapy drug-induced experiments shows that the loss of cell viability was due to
apoptosis rather than to other mechanisms of cell death.

Conclusion
Cancer therapies that function by triggering apoptosis have been used widely in
the treatment of different types of cancers for decades. Unfortunately, many types of
cancer cells are resistant to those treatments due to mutations or loss of apoptotic proteins.
For example, mutant p53 has been found in more than 50% of cancers [143]. Many
researches have shown that restoration of p53 has the potential to reduce certain types of
cancer without damaging normal cells [144]. Activation of TRAIL-induced apoptosis
pathway has also shown promise in the treatment of several types of cancers, as described
previously. In particular, several agonistic monoclonal antibodies directed against DR4
and DR5 are currently in Phase I and II clinical trials designed to evaluate their safety,
pharmacokinetics and therapeutic efficacy. For example, GS-ETR1 DR4 and HGS-ETR2
DR5 (Human Genome Sciences) are in Phase I/II trials, and HGS-TR2J DR5 (also from
Human Genome Sciences) is in Phase I. Also, as of 2008, CS-1008 (TRA-8) DR5
(Daiichi Sankyo) is in Phase I and showed no dose-limiting toxicity at doses up to 8
mg/kg [145], AMG 655 DR5 (Amgen) is in Phase I/II [146], Apomab DR5 (Genentech)
is in Phase I/II [147], and LBY 135 DR5 (Novartis) is in Phase I/II in patients with
advanced solid tumors [148]. Unfortunately, in the case of HPV-mediated cancers, E6
can bind to and accelerate the degradation of apoptotic proteins, such as FADD, caspase
8, and p53, rendering treatments that work through these pathways ineffective. By
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eliminating those apoptotic proteins and blocking apoptotic signal transduction, HPV
ensures its persistence and propagation.
Because E6 plays a key role in preventing apoptosis and promoting cancer
development, blocking its interactions with partner proteins carries with it the promise of
developing effective and novel treatments for HPV-mediated cervical cancer. Two
questions were posed at the beginning of these studies. 1) What kinds of small molecules
have ability to block interactions between E6 and apoptotic proteins? This question was
answered in Chapters 2 and 3. 2) Can those small molecules re-sensitize E6-expressing
cells to normal apoptotic stimuli? This question was also answered in Chapter 3. Results
from the experiments described in this dissertation demonstrate that the binding between
E6 and its partner proteins, caspase 8 and E6AP, can be blocked by at least two different
classes of small molecule inhibitors. Second, the blocking of E6 interactions with caspase
8 and E6AP can indeed restore the functionality of apoptosis pathways in an HPV+ cell
line. Therefore, the overall findings of this study demonstrate that small molecules
targeting E6 may indeed prove to be a potential approach to the treatment of cervical
cancer as well as other HPV-associated cancers.

Future Directions
Because DIPC can block multiple functions of HPV E6, the development of one
or more clinically-useful drugs based on this compound has great potential. As mentioned
previously, the benzimidazole family includes a number of derivatives with diverse
bioactivities, which provides a precedent for optimizing DIPC to obtain one or more
chemical compounds that can specifically block E6 functions. The next step in this
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process will be to test DIPC for function in vivo. A xenograft mouse has already been
developed in our laboratory in order to test the ability of small molecules to reduce the
development of cervical cancer. This model can be used to test DIPC as well as
additional candidates, once identified. To obtain additional and potentially more
promising candidates, we will continue searching for additional classes of small molecule
inhibitors. We have already developed collaborations with Kansas University and with
the National Center for Advancing Translational Science (NCATS) to adapt our beadbased assay to a high throughput screening (HTS) format, and look forward to obtaining
data from a screening of libraries totaling approximately 1.4 million compounds. Those
hits from HTS will be re-tested for dose-dependency in the E6/caspase 8 binding assay,
subjected to the caspase 8/caspase 8 counter-screening assay, and examined in our cell
model as described previously. Following these steps, we hope to further characterize and
optimize the best candidates, perform the appropriate in vivo studies, and move toward
clinical trials.
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